Virbac has launched Neoprinil, an eprinomectin pour-on solution indicated for use against internal and external parasites in cattle, including gut and lungworms, mange mites, sucking and chewing lice, horn flies and warbles.
Neoprinil has a zero-day withdrawal period in milk and can be administered using the company's Farmpack and Flexibag.
The Farmpack is a backpack which holds a Flexibag of Neoprinil solution. The Flexibag is a bag designed to protect medication and preserve it once it has been opened. The two together were awarded the 2014 PharmaPack Award for Innovative Packaging.
Neoprinil offers a one year stability period once it has first been opened and requires no special conditions for storage. It is presented in 2.5L, 4.5l and 8l pack sizes.
Product Manager for Large Animals Brigitte Goasduf MRCVS said: "A high worm burden can have adverse effects on the herd's productivity and performance and so it is advisable to ensure infected animals are treated as part of a Herd Health Plan. Eprinomectin is a tried and trusted parasiticide and studies confirm that it can have a positive impact on both milk production and on weight gain. Its zero day withdrawal period is a major benefit for dairy farmers.
"With the launch first of Deltanil and, now, Neoprinil, we are reinforcing our commitment to work with veterinary surgeons and farmers to understand the everyday challenges they face and to provide practical, effective solutions. We offer a comprehensive parasiticide range with a dispensing system that sets a new standard for convenience and ease of use."
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
They say this approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The researchers demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright researchers say they have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: "The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses."
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
The Pirbright Institute says there has been huge commercial interest in using this technology to develop novel vaccines, so it intends to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
Photo: Cells infected with the Marek's disease vaccine virus, HVT, (green) expressing the inserted infectious bursal disease virus gene, VP2 (red). Cell nuclei are shown in blue. © Dr Na Tang, The Pirbright Institute 2018.
Henry, who works at Crowshall Veterinary Services in Norfolk, graduated from the Royal Veterinary College in 2018.
He is the lead products export vet for Crowshall and was instrumental in the business’s preparation for Brexit.
He is also one of the founding ‘green champions’ at the practice, which has become the first specialist poultry practice to be accredited with Investors in the Environment.
The panel of seven judges from said that within just three years Henry has gained much experience, showing evidence that he has contributed to reduced antibiotic usage as well as improved biosecurity and improved bird welfare, health and production for his clients.
They said: “He has clearly shown he has worked with colleagues as a team, and has introduced new initiatives in his practice including improving mental health of staff and assisting in sustainability.”
James Porritt, National Pig and Poultry Sales Manager of award sponsors Zoetis, said all three finalists were very strong candidates: “It was great to see the work they have all done recognised at the awards.
"It was fantastic to see Henry win and hope the award spurs him on to continue his bright future in the poultry industry.”
Photo: Henry Lamb holding the Young Farm Vet trophy, alongside Jonathan Agnew (left) and James Porritt of the award sponsors Zoetis
BVA President Harvey Locke used his annual London dinner speech last night to urge the Government to take action on veterinary student fees and the welfare of dogs, and respond to the consultation on dangerous dogs.
Guests at the dinner included The Rt Hon Caroline Spelman MP, Secretary of State for Defra, parliamentarians, veterinary surgeons, and representatives from the agri-food industry, pet industry, welfare charities, research and veterinary education.
Mr Locke began by raising concerns over cuts to animal health and welfare and disease surveillance budgets: "In the Comprehensive Spending Review Defra took one of the biggest hits. The profession remains deeply concerned that cuts in research and development and disease surveillance could have catastrophic consequences. Right now the UK enjoys some of the highest animal health and welfare standards in the world and so it is in all of our interests to ensure the viability of the farming sector amidst massive competition from abroad, where those standards may not always be as high."
On veterinary student fees, Mr Locke outlined the 'double whammy' of a long course and compulsory Extra Mural Studies in the holidays: "Our role as the guardians of animal health and welfare faces an uncertain future following the announcement that the cap on tuition fees will be raised to between 6 and 9 thousand pounds a year. We fear this could have a huge impact on the decisions of A-level students, with fewer and fewer opting for an expensive veterinary science degree.
"Although the plans are not yet finalised we are bracing ourselves for veterinary degrees, which are costly to run, to be priced at the top of the scale, meaning veterinary students of the future will graduate with at least £45,000 of debt in tuition fees alone. Faced with these levels of debt, our concern is that those who do make it to graduation won't opt for the food animal practice and public health roles that attract smaller pay packages. We need to think carefully about how we can secure the future provision of large animal practitioners."
On companion animal issues Mr Locke asked Defra not to defer all decisions on dog welfare to the newly-formed Dog Advisory Council: "While the BVA fully supports the Advisory Council, we would urge the Government not to use it to delay decisions that might improve the health and welfare of dogs now. At a recent meeting of the Associate Parliamentary Group on Animal Welfare (APGAW) ...there was overwhelming support for provision for healthy breeding to be brought into Defra's welfare codes.
"We have long maintained that to ignore breeding in the dog welfare code is a serious oversight by Defra. In England we already have regulations that protect our farmed animals from breeding procedures that cause suffering or injury, but not for our pets. This contradictory approach makes little sense. Updating the welfare codes to include breeding would send a clear message that the Government is committed to improving the health and welfare of man's best friend."
On dangerous dogs Mr Locke renewed the BVA's call for the Government to respond to the Defra consultation, which found 77% in favour of scrapping breed-specific legislation: "Despite this overwhelming call from the public, the Government has kept its powder dry, repeatedly promising to announce its response soon.
"Secretary of State I would like to assure you that the BVA is prepared to work with all of the other organisations with an interest in dog welfare and public safety to find an effective solution. We all want to see people protected on private property; legislation that targets irresponsible owners and not just the way a dog looks; and tools that allow the police and other enforcement agencies to act swiftly to protect the public.
"And, crucially, we all want to work with you to achieve these aims."
SPVS is leading a ground-breaking new project which aims to find out how veterinary surgeons are treating a range of clinical conditions.
Two hundred practitioners are being sought to provide details of how they address clinical conditions in three study areas: small animal, equine and farm animal, on a new website: www.howdoido.org. The findings, which will be made anonymous, will eventually form the basis of a clinical benchmarking process, which will tie in with the growing trend towards evidence-based medicine.
SPVS's objective is to understand and support how clinicians work in practice and approach particular clinical cases. The Society is working alongside Dr Mark Johnson who carried out the Confidential Enquiry into Perioperative Equine Fatalities.
SPVS Junior Vice President Jacqui Molyneux said: "This is an exciting new study which will shed a lot of light on what we as clinicians are doing in practice with the eventual aim of developing a clinical benchmarking process.
"The project however will only be worthwhile if a significant number of practitioners take part, so we're encouraging vets to visit the website and find out more. It will take no longer than ten minutes to fill in each clinical case."
CEVA Animal Health's live enzootic abortion vaccine, CEVAC® Chlamydophila, has been renamed CEVAC® Chlamydia and repackaged in a larger bottle size.
According to the company, infectious abortion, particularly enzootic abortion (Chlamydiosis) can wipe out up to 50% of lambs but strategic use of CEVAC Chlamydia, a live enzootic abortion vaccine, can help keep the flock safe. It can prevent abortion and also control excretion and the threat of infection. For added convenience CEVAC Chlamydia can be used on the same day as the toxoplasmosis vaccine. This can save administration time and money.
For extra efficiency with big flocks CEVAC Chlamydia is now available in a larger, 50 dose bottle in addition to the original 20 dose bottle. It is administered using a special multi-dose injector gun.
CEVA says that a strategic vaccination every four years will help flocks remain chlamydiosis-free. Routine preventative measures are also advised prior to mating and when new sheep are introduced to the flock, to ensure abortion and infection rates always remain as low as possible. All animals should be vaccinated in the first year, with replacements being vaccinated from six months of age, at least four weeks prior to tupping.
For further product information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or visit the website at www.ceva.uk.com
The CPD event takes place this Thursday 9th April, from 9:30am to 5:30pm, using the Zoom video conferencing platform. The organisers say that the agenda is still being finalised, but will be split into three streams: Farm Animal, Equine and Small Animal.
Confirmed speakers include:
Although the event is free, participants are asked make a voluntary contribution at justgiving.com/fundrasing/vets-for-nhs.
To register for the event, visit www.vetsfornhs.co.uk
Vets for NHS is supported by Boehringer Ingelheim, MSD Animal Health, Nimrod and the Scottish Vet Fair.
Vetoquinol is advising vets and farmers to be on the lookout following the discovery of counterfeit Marbocyl on two farms in Northern Ireland.
The counterfeit product contains an unapproved source of Marbofloxacin in an untested formulation which presents an unknown risk to animal and human health if used.
Vetoquinol has informed the national authorities about this situation. It is illegal either to sell or supply the product or to knowingly buy and/or use it.
The withdrawal period of this counterfeit product is unknown. Should the product be used it could be detected in milk or after slaughter. Vetoquinol advises the veterinary community to be aware of the risk, to carefully check the product packaging before use and to continue to source the product from reputable suppliers.
Vetoquinol urges vets and farmers to take the following actions if you find this product on farm or are approached to purchase it:
Vetoquinol says vets can rest assured that it will do all that is necessary to remove this product from the market.
If you need further information or advice, do not hesitate to contact Vetoquinol on 0800 1698197.
Merial is highlighting the results of an independent study published in July's Journal of Dairy Science which showed that treating acutely lame cows with the non-steroidal anti-inflammatory (NSAID) Ketofen (ketoprofen), alongside therapeutic trimming and the application of a block, resulted in a significantly better recovery rate compared to the other treatment protocols used.
In the study, Evaluation of treatments for claw horn lesions in dairy cows in a randomised controlled trial by Thomas et al1, 56% of the cows in the above treatment group were observed to be sound.
Sioned Timothy, Merial Technical Veterinary Manager (pictured right) said: "The lack of evidence to underpin a standardised approach to treating lameness in cattle has previously been highlighted2.
"This study demonstrates the value of using an NSAID as part of lameness treatment both for its welfare benefits, and also to reduce the impact of lameness on herd productivity through improved recovery rates. It also highlights the importance of implementing herd health protocols that focus on early intervention – identifying cows as soon as they become lame should be a priority for dairy farmers. With lameness cited as having a significant adverse effect on milk yield3 and cull rate in the herd, a proactive approach to lameness control is critical. Farmers should work with their vets and foot trimmers to ensure that when lame cows are identified they are treated in the most effective way.”
Sioned added: "The importance of routine mobility scoring cannot be underestimated. Clinical lameness has been shown to cause a decreased milk yield from up to four months before diagnosis 3, which can translate to a mean reduction of 357 litres per 305 day lactation. Furthermore, the impact on fertility and the long term impact on replacement is also acknowledged, with lame cows less likely to conceive and having an increased risk of conception failing."
References
Colivet® solution, one of CEVA Animal Health’s range of 3 soluble antimicrobials for pigs has been renamed Coliscour®.
Phil McGuire, CEVA’s business unit manager, explains the reasoning behind the name change: “We simply felt that the easiest way to avoid confusion between our product and a totally different non-prescription product of a similar name was to give ours a new name that also reflects its use, hence Coliscour®.”
Intervet/Schering-Plough Animal Health has announced the launch of PORCILIS AR-T DF, an inactivated vaccine against progressive atrophic rhinitis in piglets with a new adjuvant which the company says is associated with fewer injection site reactions.
PORCILIS AR-T DF uses DILUVAC FORTE (DF), an aqueous vitamin E-based adjuvant and will replace PORCILIS AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring. Progressive atrophic rhinitis is caused by a toxin from the bacteria Pasteurella multocida affecting bone-forming cells in the snout of the young piglet.
Marc Dickie, Senior Director, Global Swine Business Unit at Intervet/Schering-Plough Animal Health said: "The innovative PORCILIS AR-T DF vaccine combines the proven efficacy of the current PORCILIS AR-T with an improved safety profile and convenience for the veterinarian that is offered by the aqueous DILUVAC FORTE adjuvant. The new vaccine also demonstrates the commitment of our company to continuously improve our vaccines, thereby offering value-added benefits to our customers."
Located in the South East of England, the centre is part of the new School of Veterinary Medicine at the University of Surrey, and one of the UK's largest veterinary pathology centres, offering high-containment post-mortem examination facilities and histopathology.
The centre is staffed by a team of board-certified veterinary pathologists, veterinary investigation officers and technicians, with expertise in farm-animal, equine, exotic and small-animal pathology.
The new building centres on a large containment level 2 post-mortem examination room with high ceilings, natural lighting, post-mortem examination tables, biological safety cabinets and integrated cold rooms, all served by a powerful winch system which means that post-mortem examinations can be performed on a wide range of species. A viewing gallery overlooks the suite and post-mortem examinations can be recorded and streamed for training purposes.
Professor Roberto La Ragione, Director of the Veterinary Pathology Centre, said: "Veterinary pathology is a growing discipline and its importance has been highlighted in recent disease outbreaks and the important role veterinary pathologists make in drug development. Helping the farming community to be more effective, sustainable and innovative, the Centre will work with partners, businesses and researchers to address some of the unique challenges faced by the veterinary and scientific community.
"It is the close relationships with our external clinical and scientific partners that enables us to be innovative in our approach to education and training here at the Surrey. An example of the latter is the use of digital pathology in teaching, research and diagnostics, which was the subject of discussion at the recent launch of the Veterinary Health Innovation Engine (vHive).
"Together with our partners such as the National Physical Laboratory and the 5G Innovation centre, the Centre is at the forefront of the digitalisation of pathology and innovative big data management.
"The Centre offers the opportunity to inspire the next generation of veterinary pathologists and complements the centres of excellence that already exist in other vet schools and research institutes."
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
A short survey, which has been emailed to BVA members this week, asks respondents to confirm which Official Controls Qualifications (OCQ(V)s) they currently hold or previously held.
They are also asked to give reasons if they have chosen to drop a particular qualification without revalidating it.
The BVA says members have raised concerns via Council about the OV training and revalidation process, citing time, cost, a lack of relevance and duplication of learning across different modules as reasons for choosing not to renew their qualifications.
The BVA plans to take the data and insights captured in the survey to the Animal and Plant Health Agency (APHA) and make recommendations for how the system can be made more user-friendly and fit for purpose.
John Fishwick, BVA President, said: "Official Veterinarians have a critical role to play in upholding high standards of health and welfare across the supply chain, certifying products for export and safeguarding against disease and food fraud. We are already aware that this area is facing significant challenges as Brexit is likely to drive up demand for product certification.
"It is particularly worrying to hear that members are finding the system both frustrating and resource-intensive. Losing skilled professionals now at a time when they are needed most would be a real waste of specialist knowledge and could leave gaps in the UK’s provision for responding to disease outbreaks and meeting export certification needs post-Brexit.
"We understand and support the need to keep veterinary skills up to date, but the process for demonstrating this must be straightforward and proportionate. BVA will ensure that all insights offered by respondents are raised with APHA with the aim of getting the system right for OVs working in the UK both now and in the future."
BVA members can access the survey at https://www.surveymonkey.co.uk/r/7Y2Y3RR. The deadline for responding is 29 June 2018.
Zoetis has launched a one-dose vial of Rispoval IntraNasal, in order to offer respiratory health protection in calves as soon as possible after birth without either waiting to batch them in groups or wasting unused vaccine in multi-dose packs.
To make ready for use, the vaccine is reconstituted by mixing a powder with sterile diluent. Once mixed, the licensed shelf life is two hours. This means any that is unused in multi-dose packs must be thrown away. By stocking a combination of one- and multi-dose packs, farmers can eliminate this.
The vaccine protects against two primary viral causes of pneumonia in young calves, BRSv and Pi3v1. Surveillance of blood samples from 2,145 calves with pneumonia signs found 78% exposed to BRSv, 81% to Pi3v2. The product licence allows use from nine days of age, with onset of immunity to BRSv and Pi3v after five and 10 days respectively. The licence also specifies a duration of immunity of 12 weeks.
Zoetis vet Carolyn Hogan says that viruses are the instigator of a majority of respiratory health problems: "Early-life protection also helps reduce the threat from opportunistic secondary bacterial infections, such as Pasteurella.
"Good respiratory health is essential to ensure calves develop to achieve their lifetime potential. But it's estimated that 67% of pneumonia cases occur in calves less than three months of age3.
"Whether suckled or reared, calves that don’t grow effectively in the early weeks are unlikely to catch up later. On both dairy and beef units, proactive management of the calf living space, nutrition and disease resilience is critical to maximise lifetime productivity, which is clearly so important under today's farm business economics.
More information about the benefits of managing respiratory health in calves is available at plantoproduce.co.uk.
Rexxolide contains 100 mg/ml of tulathromycin, which is widely used to treat BRD and SRD. It also has a single dose and low injection volume of 1 ml/40 kg BW, to make it more convenient.
Dechra says Rexxolide has an immune-modulating and anti-inflammatory action and offers equal viscosity and syringability as other products on the market1. It can be used for treatment and metaphylaxis of BRD and SRD and offers early-stage treatment for infectious pododermatitis.
Dechra’s Equine and Food Producing Animal Brand Manager, Emma Jennings said: “Launching Rexxolide into the market provides an alternative option to existing BRD, SRD and foot rot treatments for farm vets across the UK and Ireland.
"We support an integrated approach to the control of BRD, with good husbandry, early detection and correct therapy being vital tools in managing the multi-factorial condition."
Rexxolide is available in 50ml and 100ml vials. For more information visit www.dechra.co.uk.
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
As Ceva points out, the change gives veterinary surgeons an opportunity to get more involved in parasite control plans and help farmers develop a sustainable parasite control strategy on their farm.
Eprecis injectable contains eprinomectin, the only molecule with zero-milk withdrawal currently available for cattle on the U.K. market.
Ceva highlights that because Eprecis is an injection, there is no risk of product transfer between in-contact animals caused by licking1,2,3 a natural behaviour of cattle, potentially resulting in sub-therapeutic levels of product being absorbed. There is also no risk of reduction in efficacy if dirt or manure is present on the back of the animal4.
The company says injectable formulation results in less active ingredient per animal treated compared to eprinomectin pour-ons; for example using Eprecis injection, a 500kg animal receives 100mg eprinomectin, while a pour-on delivers 250mg per application.
To support the new POM-V classification, Ceva has launched a vet support pack to help veterinary professionals when talking to their farming clients about Eprecis, worming strategies and their parasite control plans. The pack contains a farmer targeted brochure, farmer Q&A and a practical guide with suggestions of when Eprecis can be used. It also includes an infograph for social media posts, a technical booklet and a vet Q&A to help answer the most common questions they may be asked. A series of social media posts are available for vet practices encouraging their clients to discuss worming with their vet.
Kythé Mackenzie BVSc MRCVS, ruminant veterinary adviser at Ceva Animal Health, said: “Ruminants can be parasitised by a range of nematodes, trematodes and external parasites, all of which can have an impact on health and production. A recent publication considered that helminth infections (GIN, lungworm and liver fluke) cost the UK dairy industry close to £145M per year5. Interestingly, the majority of these costs were attributed to lost production (£131M) rather than treatment costs (£14M).
“There is now documented resistance to eprinomectin in small ruminants6 (Haemonchus contortus in goats) and whilst not yet documented in cattle, action needs to be taken to try and delay/minimise this emergence. This requires the use of more sustainable parasite control plans to assist in managing refugia and allowing animals adequate exposure to the parasites to develop natural immunity. Parasite control plans should maximise health, welfare and production whilst minimising the unnecessary use of anthelmintics.”
In the short-term, orders of Eprecis injectable from veterinary wholesalers will be fulfilled by the current POM-VPS product that is in the supply chain before switching to the new packaging later in the season.
For further information contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
The tracker, which Elanco produces with NADIS (National Animal Disease Information Service), highlights areas hit with blowfly strike in real-time, to provide a warning for farmers, veterinary surgeons and industry professionals.
The first reported incidents were in Hampshire, before spreading across Devon, West Sussex, and Buckinghamshire. Elanco says particularly severe cases include a flock in Dorset, in which 50% of a lamb group have been hit by blowfly strike. Latest reports are in northern England and some initial cases in Scotland.
The company says its blowfly risk forecast suggests that weather conditions from southern England and Wales to the Midlands mean that flies are now active, and females are laying eggs that could result in serious welfare and productivity issues.
Richard Wall, Professor of Zoology at Bristol University, said: "The timing and severity of blowfly strike is strongly influenced by the weather. This is a reminder to farmers that now is the time to act for early prevention. Delaying treatment not only costs the farm but risks the welfare and productivity of the flock."
Fiona Hutchings, Technical Vet at Elanco, said: "The costs of inaction when it comes to blowfly strike far outweigh the costs of protection. With 99% of farmers having suffered financial losses as a result of blowfly strike¹, the potential impact on your flock simply isn’t worth the risk. Farms need to take control — and take control early — by using a preventative IGR product with full fleece protection2."
Fiona added: "By the time symptoms show themselves, it’s often too late. It’s easy to overlook even one struck sheep, and blowfly strike can cause huge damage in very little time. In addition, using protection early reduces risk later in the season by ensuring a much lower fly count as the season progresses."
CEVA Animal Health has launched Marbokem, a Marbofloxacin-based antimicrobial for the treatment of respiratory disease in cattle which offers the advantages of a one-shot protocol and a shock-resistant vial.
Marbokem is used for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. CEVA says Marbofloxacin's efficacy has been proven in terms of re-treatment rate, success, speed of action and MICs in comparison with many frequently used quinolones and macrolides. (1,2,3,4)
According to CEVA, Marbokem's one shot protocol means it's quick and economical to use, while its presentation in an ergonomic CLAS vial makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. The company says Marbokem is also very competitively priced.
For further product information, please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
1 Grandemange, E., Fournel, S., Woerhle, F. (2009) Field evaluation of the efficacy of 2 antibiotics in treating bovine respiratory infections. Poster, Journées Nationales des GTV, Nantes, France. 2. Grobbel, M., Lübke-Becker, A., Wieler, L., Froyman R., Friederichs, S., Filios, S. (2007) Comparative quantification of the in-vitro activity of veterinary fluoroquinolones. Veterinary microbiology 124 (73-81). 3. Roy, O., Pillet, F., Heurtin-Vallé, A., Frontczak, N. (2008) Comparative field clinical efficacy of a single intramuscular injection of marbofloxacin in the treatment of bovine respiratory disease. Poster, World Buiatrics Congress, Budapest, Hungary.4. Wu, C. (2004) Determination of minimum inhibitory concentrations of danofloxacin and other commonly used cattle antimicrobial agents against Mycoplasma bovis isolated from cattle with clinical disease. Le médecin vétérinaire du Québec. 34 (1-2).
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
Gabbrovet Multi is the first and only ready-to-use solution licensed to treat both cryptosporidium and E.coli diarrhoea in calves.
The company highlights a study of 334 calves with severe diarrhoea, where those receiving Gabbrovet Multi showed a faster and more effective response than those given halofuginone1.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Gabbrovet Multi is the first and only ready-to-use solution for the convenient treatment of both cryptosporidium and E.coli, two of the most common causes of neonatal scour in calves."
Gabbrovet Multi can be administered in milk or water.
It is available with a dosing cap and comes in 250ml, 500ml or 1l presentations.
Gabbrovet Multi also treats gastro-intestinal infections caused by E.coli in pigs.
For further information, contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
This third biennial offering from GB’s Cattle Health and Welfare Group also contains a summary of progress on endemic disease control with advances in eradicating Bovine Viral Diarrhoea (BVD) in each country highlighted.
The Chief Veterinary Officers of UK, Scotland and Wales have welcomed the publication of the report saying that as the possible impacts of the referendum on leaving the EU are considered, the importance of a GB focus on disease control is as important as ever.
In their joint forward, Nigel Gibbens, Sheila Voas and Christianne Glossop said: "The healthier our animals, the more attractive our products. The better our animal welfare, the greater the confidence of consumers in our production systems.
"With the UK Government placing AMR at the top of its risk register alongside terrorism and pandemic ’flu, it is heartening to see that CHAWG, in common with other livestock sectors, has grasped the nettle in looking first at how the cattle sector can better capture data on use of antimicrobials."
They go on to say that addressing AMR helps address other imperatives as an emphasis on sound animal husbandry and healthy animals kept to high welfare standards will help minimise routine reliance on antimicrobials: "Success in controlling endemic disease is one area of considerable importance, and here we can highlight CHAWG’s pivotal role in the development and promotion of national disease control programmes. These include the launch of the BVDFree scheme in England earlier this year, ongoing progress with BVD eradication in Scotland, the development of a Wales BVD scheme, and the Action Johne’s initiative."
In the report’s conclusion, RSPCA’s head of farm animals Marc Cooper points out that it is clear many positive initiatives are being pursued within the industry. He said: "Notable amongst these are those associated with dairy cow genetics, eliminating BVD, the national dairy cow welfare strategy and the development of a data hub for the collation of information relating to antimicrobial use.
"Indeed, some of these are starting to realise improvements in key areas, for example, dairy cow longevity is beginning to increase, and cow fertility figures and somatic cell counts appear to be moving in the right direction.
"However, there are still ongoing concerns relating to some important health and welfare issues. For example, despite the evidence suggesting the annual prevalence levels of cattle lameness are beginning to fall, there still appears to be no centralised database for recording it."
Chairman of CHAWG Tim Brigstocke says the contributed comments are encouraging and provide positive direction for future CHAWG activities. He also reassures that while this report sees a number of advances in highly topical areas, ‘core’ activities are not being ignored. He said: "Effective farm health planning remains the bedrock of good practice. And while we tend to focus on areas which need improvement, it’s worth mentioning that a delegation from the Food & Veterinary Office (FVO) of the European Commission recently visited and were impressed by the coordinated approach taken in this country."
The report can be downloaded from www.chawg.org.uk.
Metaxol contains 20 mg trimethoprim and 100 mg sulfamethoxazole per ml and can be added directly to drinking water or used in a concentrated stock.
The new product, which is part of the company's SoluStab range, replaces Methoxasol. Dechra says it is likely to be welcomed by farmers wanting to target entire flocks because of its shorter withdrawal time for broilers.
Dechra Brand Manager Emma Jennings said: "Sulfamethoxazole is a potent sulfonamide and, when combined with trimethoprim, it has a synergistic and bactericidal effect.
"Both active ingredients are rapidly absorbed and distributed widely in tissues making it a highly effective treatment.
"The shorter withdrawal time for broilers will make it an attractive treatment for farmers wanting to target entire flocks."
Metaxol is not suitable for laying hens.
In fattening pigs, Metaxol is suitable for the treatment and metaphylaxis of post-weaning diarrhoea caused by beta-haemolytic K88-positive, K99-positive or 987P Escherichia coli strains susceptible to trimethoprim-sulfamethoxazole.
It can also be used for secondary bacterial infections caused by Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus spp. and Haemophilus parasuis susceptible to trimethoprim-sulfamethoxazole.
In broilers, it can be used for treatment and metaphylaxis of Colibacillosis caused by Escherichia coli susceptible to trimethoprim-sulfamethoxazole or Coryza caused by Avibacterium paraga.
The recommended dosage is 0.25 ml of product per kg body weight per day for four to seven days for pigs and 0.38 ml of product per kg body weight per day for three days for chickens.
For support in calculating dosages, visit http://calculator.solustab.eu/.